If you're already researching semaglutide, you've probably run into the name CagriSema. It's not a new drug so much as a pairing, cagrilintide added to semaglutide. And the question that actually matters before you look into it further isn't "does adding more peptide help," it's "what is cagrilintide even doing that semaglutide isn't already doing." That second question has a real answer.
Two different pathways, not one pathway twice
Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that tells your brain and pancreas you've eaten, which is most of why it reduces appetite and slows digestion. Cagrilintide is something else entirely, a long-acting version of amylin, a hormone your pancreas already releases alongside insulin.
Amylin acts on receptors in the brainstem and hypothalamus, the same general neighborhood as GLP-1's targets, but through a separate set of receptors. Researchers describe the two pathways as complementary rather than redundant, meaning they appear to influence appetite and fullness through different signals rather than both pulling the same lever harder. That's the actual rationale for combining them. It's not "more GLP-1," it's "a second, different signal working alongside the first one."
What the trials found
The combination has been studied in two Phase 3 trials, both published in 2025. REDEFINE 1 looked at CagriSema (cagrilintide and semaglutide, both dosed at 2.4 mg weekly) in adults with overweight or obesity, and researchers reported an average weight reduction of about 22% over 68 weeks. REDEFINE 2 studied the same combination in adults who also had type 2 diabetes, a group where GLP-1 therapy alone typically produces smaller results, and still found meaningful reductions compared to semaglutide by itself.
Before those larger trials, a Phase 1b study looked specifically at safety and tolerability when the two compounds were given together. It found a gastrointestinal side effect pattern broadly similar to semaglutide alone, nausea and digestive symptoms being the most common complaints, which is reassuring in the sense that adding cagrilintide didn't appear to introduce a new category of problem. That earlier safety data is part of what supported moving into the larger REDEFINE trials.
What's still unresolved
Almost everything published on cagrilintide has studied it alongside semaglutide, not as a standalone compound. That makes it genuinely hard for researchers to say how much of the extra weight loss comes specifically from the amylin pathway versus the GLP-1 pathway working a little better in combination. It's a real limitation, and it's one of the reasons the research community is still cautious about overstating what "adding cagrilintide" does on its own.
This is research information, not a treatment plan, and nothing here is a recommendation to combine anything. Whether and how to research this further, and whether to loop in a doctor who understands peptide research, is your call.
Where to go from here
If you want the full citation list and study breakdown behind the numbers above, the Cagrilintide research notes and Semaglutide research notes pages carry the sourced detail this guide summarizes.
This is the first piece in a short series on stacking cagrilintide with GLP-1 compounds. The cagrilintide-plus-tirzepatide and cagrilintide-plus-retatrutide pieces will follow once there's real research to report on, rather than speculation dressed up as an article. In the meantime, you can compare current cagrilintide and semaglutide pricing across vendors in the free tool.